X0306 4 2022-01-01 0 0001652130 Intellia Therapeutics, Inc. NTLA 0001777421 Sepp-Lorenzino Laura C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 0 1 0 0 EVP, Chief Scientific Officer Common Stock 2022-01-01 4 M 0 3500 A 5963 D Common Stock 2022-01-01 4 S 0 1148 112.25 D 4815 D Common Stock 2022-03-01 4 A 0 13816 0.00 A 18631 D Restricted Stock Unit 2022-01-01 4 M 0 3500 0.00 D 2022-01-01 2031-03-02 Common Stock 3500 10500 D Stock Option (right to buy) 79.85 2022-03-01 4 A 0 13816 0.00 A 2032-02-28 Common Stock 13816 13816 D Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Includes 72 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2021. Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. James Basta, attorney-in-fact 2022-03-03